TY - JOUR
T1 - Clinical features affecting survival in metastatic NSCLC treated with immunotherapy
T2 - A critical review of published data
AU - Passaro, Antonio
AU - Attili, Ilaria
AU - Morganti, Stefania
AU - Del Signore, Ester
AU - Gianoncelli, Letizia
AU - Spitaleri, Gianluca
AU - Stati, Valeria
AU - Catania, Chiara
AU - Curigliano, Giuseppe
AU - de Marinis, Filippo
N1 - Funding Information:
This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds.
Publisher Copyright:
© 2020 Elsevier Ltd
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9
Y1 - 2020/9
N2 - Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patients achieve a broad and durable benefit and another proportion report poor survival and sometimes fast disease progression, confirming the need to optimise the patient's selection. To date, several issues are unsolved about how to personalise the immunotherapy treatment for individual patients. In this review, analysing data from pivotal randomised clinical trials (RCTs), we discuss patient baseline clinical and demographic features, including sex, age, ECOG performance status, smoking habit and specific site of metastases (liver, bone and brain) that may influence the efficacy outcomes in patients treated with ICIs. The high performance of the ICIs blurred the vision on different efficacy-limiting factors, which require extensive evaluation to improve the understanding of the tumour-specific immune response, in which clinical drivers could be useful for better patient stratification.
AB - Immune checkpoint inhibitors (ICIs) represent one of the main steps forward for the treatment of advanced or metastatic non-small-cell lung cancer (NSCLC), without oncogenic driver alterations. Despite this recent progress, only a minority of patients achieve a broad and durable benefit and another proportion report poor survival and sometimes fast disease progression, confirming the need to optimise the patient's selection. To date, several issues are unsolved about how to personalise the immunotherapy treatment for individual patients. In this review, analysing data from pivotal randomised clinical trials (RCTs), we discuss patient baseline clinical and demographic features, including sex, age, ECOG performance status, smoking habit and specific site of metastases (liver, bone and brain) that may influence the efficacy outcomes in patients treated with ICIs. The high performance of the ICIs blurred the vision on different efficacy-limiting factors, which require extensive evaluation to improve the understanding of the tumour-specific immune response, in which clinical drivers could be useful for better patient stratification.
UR - http://www.scopus.com/inward/record.url?scp=85089064323&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089064323&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2020.102085
DO - 10.1016/j.ctrv.2020.102085
M3 - Review article
C2 - 32771858
AN - SCOPUS:85089064323
VL - 89
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
M1 - 102085
ER -